BioNTech SE 4

BioNTech SE CCO Annemarie Hanekamp received new option and performance share unit awards totaling 22,655 ordinary-share-equivalent units as equity compensation on May 12, 2026.

On May 12, 2026, BioNTech SE Chief Commercial Officer Annemarie Hanekamp received two equity-based compensation grants: a stock option award for 12,586 ordinary-share-equivalent units with an exercise price of EUR 89.38 and a performance share unit (PSU) award for 10,069 units, each PSU economically equivalent to one ordinary share or ADS. Both the option and PSU grants vest in equal annual installments over four years starting on the first anniversary of the grant date and become exercisable four years after grant, subject to performance and service conditions, and may be settled in ordinary shares, ADSs, and/or cash at the company’s election. These are new awards (coded as acquisitions) intended as long-term, performance-based compensation; no open-market purchases or sales were reported, and post-transaction beneficial ownership is reported as 12,586 option rights and 10,069 PSUs held directly.

Filing Facts

CIK

1776985

Ticker

BNTX

Form

4

Source Type

sec

Accession

0002118987-26-000002

Alert Tier

5